Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European Parliament debate on embryonic stem cell research funding:

This article was originally published in Clinica

Executive Summary

A lively debate has taken place at the European Parliament on the question of whether stem-cell research should be financed through EU funding. While there are still huge differences of opinion between the MEPs, the scientists and member states, the aim is to achieve an eventual compromise on many of the issues. The European Commission hopes to draw up a proposal for establishing guidelines for deciding on EU funding of research projects involving the use of human embryos and human embryonic stem cells. The EP'sdiscussion is pivotal to the future of medicine: if stem cells can cure some diseases, such as multiple sclerosis (where there has been great success in trials with mice), there will be a significant shift in the need for other interventions and treatments for such diseases in the future.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT062035

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel